PCSK9 and hepatocellular carcinoma: Taken together, flubendazole increases the cellular uptake of cholesterol in HCC cells by inhibiting PCSK9, which results in suppressed cholesterol levels modified with SMO and leads to the inhibition of the Hh signaling pathway.